Promimic AB (publ) (PRO.ST)
SEK 25.8
(-1.15%)
SEK 25.8
(-1.15%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 48.55 Million SEK | 47.14% |
| 2022 | 32.99 Million SEK | 42.09% |
| 2021 | 23.22 Million SEK | 20.02% |
| 2020 | 19.35 Million SEK | 15.17% |
| 2019 | 16.8 Million SEK | 1680099900.0% |
| 2018 | 1.00 SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 12.98 Million SEK | -13.49% |
| 2024 Q2 | 14.85 Million SEK | 14.41% |
| 2023 Q1 | 9.96 Million SEK | 1.38% |
| 2023 FY | 48.55 Million SEK | 47.14% |
| 2023 Q4 | 15.01 Million SEK | 32.26% |
| 2023 Q2 | 12.4 Million SEK | 24.48% |
| 2023 Q3 | 11.35 Million SEK | -8.53% |
| 2022 Q4 | 9.83 Million SEK | 23.81% |
| 2022 Q3 | 7.94 Million SEK | -4.26% |
| 2022 Q2 | 8.29 Million SEK | 16.03% |
| 2022 Q1 | 7.14 Million SEK | -8.6% |
| 2022 FY | 32.99 Million SEK | 42.09% |
| 2021 Q1 | - SEK | 0.0% |
| 2021 FY | 23.22 Million SEK | 20.02% |
| 2021 Q2 | - SEK | 0.0% |
| 2021 Q4 | 7.82 Million SEK | 56.94% |
| 2021 Q3 | 4.98 Million SEK | 0.0% |
| 2020 FY | 19.35 Million SEK | 15.17% |
| 2019 FY | 16.8 Million SEK | 1680099900.0% |
| 2018 FY | 1.00 SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | 41.398% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 92.064% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 92.064% |
| Arcoma AB | 53.25 Million SEK | 8.826% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | -877.098% |
| BICO Group AB (publ) | 2.84 Billion SEK | 98.295% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | 76.929% |
| CellaVision AB (publ) | 295.99 Million SEK | 83.597% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | 29.563% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -3608.572% |
| C-Rad AB (publ) | 3.8 Million SEK | -1177.684% |
| Duearity AB (publ) | 21.58 Million SEK | -124.934% |
| Dignitana AB (publ) | 74.73 Million SEK | 35.035% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -1698.222% |
| Getinge AB (publ) | 10.75 Billion SEK | 99.549% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | -166.351% |
| Iconovo AB (publ) | 63.35 Million SEK | 23.364% |
| Integrum AB (publ) | 90.57 Million SEK | 46.394% |
| Luxbright AB (publ) | 23.09 Million SEK | -110.268% |
| Mentice AB (publ) | 237.06 Million SEK | 79.519% |
| OssDsign AB (publ) | 175.6 Million SEK | 72.351% |
| Paxman AB (publ) | 133.8 Million SEK | 63.713% |
| Qlife Holding AB (publ) | 162.38 Million SEK | 70.101% |
| SciBase Holding AB (publ) | 69.97 Million SEK | 30.616% |
| ScandiDos AB (publ) | 61.03 Million SEK | 20.456% |
| Sectra AB (publ) | 39.06 Million SEK | -24.292% |
| Sedana Medical AB (publ) | 174.52 Million SEK | 72.181% |
| Senzime AB (publ) | 141.51 Million SEK | 65.692% |
| SpectraCure AB (publ) | 12.12 Million SEK | -300.33% |
| Stille AB | 87.21 Million SEK | 44.333% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 99.128% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | 88.989% |